Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

NCT02631044 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

387

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle-cell Lymphoma
Primary Mediastinal B-cell Lymphoma

Interventions

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) single-dose schedule
BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) 2-dose schedule

Sponsor

Juno Therapeutics, a Subsidiary of Celgene